VNRX volition.com Earnings per share growth in current year

Official company branding of volition.com (VNRX)

VolitionRx Limited leads in epigenetic oncology screening by investing in the unique Nucleosomics technology. Year-over-year changes in EPS reflect capital dynamics, where the value of 55.60 expresses the metric level. AI-powered robotic systems accelerate blood analysis, providing the company with a competitive advantage due to the platform's versatility in both human and veterinary medicine.

Earnings per share growth in current year: VolitionRx Limited (VNRX) for 07/04/2022 - 11/15/2026

Analytical breakdowns and data insights for company VolitionRx Limited (VNRX)

- market value and analyst target forecast:
Stock Price VolitionRx Ltd|VNRX - Price Target Chart
- market capitalization data:
Market Value VolitionRx Ltd.|VNRX - Real Price to Acquire Entire Company
- book capitalization indicators:
Net Asset Value per Share VolitionRx|VNRX - Company Book Value|Market Capitalization to Book Value volition.com|VNRX - Company Total Assets
- debt and solvency information:
Total Debt to Capital Coefficient VolitionRx Limited|VNRX - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient VolitionRx Limited|VNRX - Company Total Debt|Debt to Book Capitalization Ratio VolitionRx Limited|VNRX - Company Long-Term Debt|Short-Term Debt VolitionRx|Quick Liquidity volition.com
- company profitability and valuation multiples indicators:
VNRX - Net Profit|Company Profit Forecast VolitionRx Limited|VNRX - Price to Earnings Ratio|Market Cap to Future Earnings Ratio VolitionRx Ltd.|VNRX - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio VolitionRx Limited|VNRX - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months VolitionRx|VNRX - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months volition.com|VNRX - Earnings per share growth in current year|Expected earnings per share trend next year VolitionRx Limited
- revenue and sales proceeds data:
VNRX - Company Sales|Company Revenue Forecast VolitionRx Limited|VNRX - Market Cap to Revenue|Forward Price to Sales VolitionRx Limited|VNRX - Sales Growth YoY (Last Twelve Months)
Summary company analysis:volition.com, VNRX
Mass-produced product of VolitionRx Ltd

Investors use this indicator as a leading signal for future stock returns. The metric captures the percentage deviation of current earnings per share from the same value last year. Current annual EPS progress has reached 55.60. This price action reflects the monetization efficiency of the Nu.Q platform. The strong pricing power of VolitionRx Limited (VNRX) in the early cancer diagnostics segment converts directly into the growth of this fundamental indicator.

Main competitors

CAI (Caris Life Sciences, Inc.) - Earnings per share growth in current year|Earnings per share growth in current year guardanthealth.com|Earnings per share growth in current year VCYT|Net earnings per share growth this year CELC (Celcuity Therapeutics)|GRAL - Earnings per share growth rate in current year|Earnings per share growth in current year Myriad MYGN|Expected net earnings per share growth this year Castle Biosciences Corp (CSTL)|BNR - Earnings per share growth in current year|Expected net earnings per share growth this year biodesix.com BDSX|Precipio Inc. (PRPO) - Earnings per share growth in current year|CHEK - Expected net earnings per share growth this year|Earnings per share growth in current year mainzbiomed.com|Earnings per share growth this year OCX (OncoCyte Corp.)